Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Pharmaceutical company historically a generics player (US, UK, India) that has repositioned around research-led assets: novel antibiotics for drug-resistant infections (including Zaynich/zidebactam combinations and other NCEs) and a biologics portfolio led by insulin and insulin analogues. Retains branded generics operations in India and emerging markets after years of restructuring and asset sales (its domestic branded portfolio was partly sold to Dr. Reddy's in 2020). Revenue is driven by UK/EU generics, India business and the ramp of new antibiotic/insulin franchises.
A niche Indian pharma company notable for one of the few new-antibiotic discovery pipelines globally.
Wockhardt Ltd. is a constituent of NIFTY 500, NIFTY PHARMA, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Wockhardt Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 13.12 | -3.02 | -32.05 |
| Book value / share (₹) | 325.99 | 287.47 | 237.79 |
| Return on equity | 4.0% | -1.0% | -12.6% |
| Return on capital employed | 6.1% | 2.9% | -3.8% |
| Operating margin | 12.6% | 5.8% | -6.6% |
| Net margin | 5.9% | -1.9% | -16.9% |
| EBITDA | ₹652 Cr | ₹393 Cr | ₹39 Cr |
| Free cash flow | ₹254 Cr | ₹-116 Cr | ₹160 Cr |
| Total debt | ₹2,125 Cr | ₹1,859 Cr | ₹2,112 Cr |
| Debt to equity | 0.40 | 0.40 | 0.58 |
| Interest coverage | 2.0 | 0.7 | -0.6 |
| Current ratio | 1.61 | 1.21 | 0.74 |
| Shares outstanding | 16,20,00,000 | 16,20,00,000 | 15,40,00,000 |
Open the full income statement, balance sheet and cash flow for WOCKPHARMA →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.